Colleen Lewis

TL;DR: The outcomes of a cohort of patients with cancer and COVID-19 are characterised and potential prognostic factors for mortality and severe illness are identified and race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.

TL;DR: For example, the authors found that 60% of the participants in phase 1 trials had therapeutic misestimation, defined as incorrectly estimating the chance of a research trial benefit as >20% or underestimating risk as 0%.

TL;DR: The authors investigated the association between these markers and clinical outcomes of patients with advanced‐stage cancer who received IO.

TL;DR: The presence of liver metastases may be a poor prognostic factor in patients receiving IO on phase 1 clinical trials and warrant consideration in updated prognostic models if these findings are validated in a larger prospective cohort.

TL;DR: A phase 1b trial of carboplatin, cetuximab, and everolimus for untreated RMSCCHN and preclinical studies suggested that mammalian target of rapamycin inhibitors may overcome resistance to epidermal growth factor receptor blockers and may augment cetUXimab antitumor activity.